| Literature DB >> 32078034 |
Gustavo C Leal1,2,3, Igor D Bandeira2,3, Fernanda S Correia-Melo2,3, Manuela Telles2,3, Rodrigo P Mello2,3, Flavia Vieira2,3, Cassio S Lima2,3,4, Ana Paula Jesus-Nunes2,3, Lívia N F Guerreiro-Costa2,3, Roberta F Marback2, Ana Teresa Caliman-Fontes2, Breno L S Marques2,4, Marília L O Bezerra2,4, Alberto L Dias-Neto2, Samantha S Silva2, Aline S Sampaio2,3,5, Gerard Sanacora6, Gustavo Turecki7, Colleen Loo8, Acioly L T Lacerda9,10, Lucas C Quarantini11,12,13,14.
Abstract
We aimed to analyze the efficacy and safety of arketamine, the R(-)-enantiomer of ketamine, for treatment-resistant depression (TRD) in humans. Open-label pilot trial, seven subjects with TRD received a single intravenous infusion of arketamine (0.5 mg/kg); primary outcome was change in Montgomery-Åsberg Depression Rating Scale (MADRS) 24 h after. Mean MADRS dropped from 30.7 before infusion to 10.4 after one day, a mean difference of 20.3 points [CI 95% 13.6-27.0; p < 0.001]; dissociation was nearly absent. Arketamine might produce fast-onset and sustained antidepressant effects in humans with favorable safety profile, like previously reported with animals; further controlled-trials are needed.Entities:
Keywords: (R)-Ketamine; Arketamine; Ketamine; Major depressive disorder; Rapid-acting antidepressant; Treatment-resistant depression
Year: 2020 PMID： 32078034 DOI： 10.1007/s00406-020-01110-5
Source DB: PubMed Journal: Eur Arch Psychiatry Clin Neurosci ISSN： 0940-1334 Impact factor: 5.270